Ras Al Khaimah, UAE: Gulf Pharmaceutical Industries PSC (Julphar), one of the largest pharmaceutical manufacturers in the Middle East and Africa, announced today the launch of its AED 500 million rights issue as the company progresses on its ambitious turnaround plan. The rights issue is set to improve the company’s capital position and debt profile and will provide the financial foundation for the successful implementation of the company’s medium-term growth strategy.
As part of its capital restructuring, which included a capital reduction of AED 503 million as an initial step, Julphar offers 500 million new shares with a nominal value of AED 1. Issued to existing shareholders, the new shares will provide investors with the same rights - including the right to receive all future dividends - as existing shares. The subscription period of the shares begins on 29 June 2020 and ends on 12 July 2020.
Commenting on the launch of the rights issue, His Highness Sheikh Saqer Humaid Al Qasimi, Chairman of the Board, Julphar, said: “The rights issue is a key component of the transformation plan which I am confident will further help us fuel our growth agenda in the years to come. On this occasion, I would like to thank our shareholders for their continued trust and their confidence in our ability to strengthen Julphar’s operational and financial performance. Our business fundamentals are robust and we have the experience, capabilities and resources to unlock further growth potential in our core markets.”
The capital restructuring and the terms of the rights issue were approved by Julphar’s Board of Directors and shareholders at the company’s Annual General Assembly held in April 2020. The rights issue has also been approved by the Security and Commodities Authority (SCA) of the UAE.
“In the past few months, we have accelerated our transformation journey to reclaim Julphar’s leadership position in the MENA region,” said Dr. Essam Farouk, Chief Executive Officer of Julphar. “The AED 500 million rights issue is central to our turnaround strategy, which capitalizes on Julphar’s core competencies to strengthen our balance sheet and invest in sustainable growth opportunities, while creating sustainable shareholder value. We are working on several strategic initiatives to move us towards a cash positive position and bring Julphar back to profitability.”
In addition to improving its capital structure and balance sheet, the newly injected capital is expected to help expand Julphar’s operations in key markets including Saudi Arabia, Iraq and Egypt. Earlier this year, Julphar announced the relaunch of over 80 products in both Saudi Arabia and Oman after the confirmation of its full compliance with Good Manufacturing Practices (GMP) through an inspection conducted by the Gulf Health Council (GHC) and the Saudi Food and Drug Authority (SFDA).
Julphar was established in 1980 and registered as a national UAE public shareholding company with a mission to provide a better quality of life for the people by delivering best in class solutions and real value through a wide range of products such as medicines, vaccines and consumer healthcare products.
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
